clinical trial · NCT07226206
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Hoffmann-La Roche·phase2·not yet recruiting·n = 5
Hemophilia ASPK-8011QQ
brief summary
This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.
started
Mar 31, 2026
primary completion
Jul 31, 2031
completion
Jul 31, 2031
last updated
Mar 31, 2026
official title
A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol